文献速递神经肿瘤

GLIMMER:术中高光谱成像预测胶质瘤MGMT启动子甲基化的中期亚组分析

GLIMMER: an interim subgroup analysis from an ongoing prospective study evaluating hyperspectral imaging for MGMT promoter methylation in gliomas.
PubMed 文献 · J Neurooncol · 2025-11-17

该前瞻性单中心观察性研究纳入25例胶质瘤患者,术中行高光谱成像(500-1000 nm)提取TWI和OHI构建三点GLIMMER评分,以焦磷酸测序测MGMT启动子甲基化为主要终点。GLIMMER评分AUC为0.95(95%CI 0.87-1.00),灵敏度94.7%、特异度83.3%;IDH野生型胶质母细胞瘤亚组(n=16)AUC为0.97、灵敏度100%、特异度75%。评分≥1分者MGMT甲基化比例31.5%,显著高于0分者的7.9%(p<0.001)。

要点

  • GLIMMER评分可术中快速无创估测MGMT启动子甲基化,AUC达0.95。
  • IDH野生型胶质母细胞瘤亚组诊断性能更高,AUC为0.97、灵敏度100%。
  • 评分≥1分者MGMT甲基化比例显著高于0分者,提示可辅助切除策略决策。

核心结论

  • GLIMMER评分提示术中高光谱成像可超快速、无创估测胶质瘤MGMT启动子甲基化,诊断性能较高。
  • 研究结论需进一步用术中高光谱成像引导活检验证,以指导未来胶质瘤个性化切除策略。

研究设计与样本

  • 前瞻性单中心观察性研究的中期亚组分析,纳入25例胶质瘤患者。
  • 患者切除术中靶向非对比增强肿瘤区域行在体高光谱成像,光谱范围500-1000 nm。
  • 提取组织水指数(TWI)和器官血红蛋白指数(OHI),组合为新型三点GLIMMER评分。
  • 主要终点为焦磷酸测序确定的MGMT启动子甲基化状态,并设IDH野生型胶质母细胞瘤亚组(n=16)。

主要发现

  • OHI≤0.606和TWI≥0.501与MGMT启动子甲基化显著相关。
  • 联合GLIMMER评分AUC为0.95(95%CI 0.87-1.00),灵敏度94.7%、特异度83.3%。
  • 胶质母细胞瘤亚组AUC为0.97,灵敏度100%、特异度75%。
  • 评分≥1分者MGMT甲基化比例为31.5%,显著高于0分者的7.9%(p<0.001)。

关键数值与推荐

  • GLIMMER评分为三点光学评分,由OHI≤0.606和TWI≥0.501两个参数组合构成。
  • 主要终点以焦磷酸测序判定MGMT启动子甲基化状态。
  • 诊断性能以AUC、灵敏度和特异度衡量。

临床怎么用

  • 术中高光谱成像有望在手术室超快速、无创提供MGMT启动子甲基化信息。
  • 评分结果或可辅助胶质瘤患者个性化切除策略的制定。
  • 结论尚需术中高光谱成像引导活检的进一步验证后方可用于临床决策。

局限性

  • 本研究为单中心观察性研究的中期亚组分析,样本量25例。
  • 胶质母细胞瘤亚组样本量为16例。
  • 作者指出 findings 需进一步验证,尚未确立临床常规应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MGMT promoter methylation is of importance in glioma regarding prognosis and management. Non-methylated MGMT glioblastoma patients seem to benefit more from gross total resection. MGMT status is not ultra-rapidly available in the operating room. The presents study is the first aiming to evaluate whether the novel imaging technique intraoperative hyperspectral imaging (HSI) can predict MGMT promoter methylation status in glioma patients using a novel optical scoring system. METHODS: This was a prospective subgroup analysis of 25 glioma patients enrolled in a single-center observational study. Patients underwent in-vivo HSI (spectral range: 500-1000 nm) targeting non-contrast-enhancing tumor regions during resection. Two optical parameters-tissue water index (TWI) and organ hemoglobin index (OHI)-were extracted and combined into a novel three-point GLIMMER score. Primary endpoint was MGMT promoter methylation status determined by pyrosequencing. Diagnostic performance of the GLIMMER score was measured by AUC, sensitivity, and specificity. A subgroup analysis focused on IDH-wild-type glioblastoma (n = 16). RESULTS: OHI ≤ 0.606 and TWI ≥ 0.501 were significantly associated with MGMT promoter methylation. The combined GLIMMER score achieved an AUC of 0.95 (95% CI, 0.87-1.00) with 94.7% sensitivity and 83.3% specificity. In the glioblastoma subgroup, the AUC was 0.97, with 100% sensitivity and 75% specificity. Patients scoring ≥ 1 point had significantly higher MGMT methylation (31.5%) than those scoring 0 points (7.9%; p < 0.001). CONCLUSIONS: The GLIMMER score suggests potential ultra-rapid, non-invasive intraoperative estimation of MGMT promoter methylation with high diagnostic performance. These findings necessitate further validation with in-vivo HSI-guided biopsies to guide future personalized resection strategies in glioma patients. CLINICAL TRIAL NUMBER: German Clinical Trials Register (DRKS, Trial number: DRKS00036771, Registration date: 05.05.2025).

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Wach J, Weber F, Wende T, et al. GLIMMER: an interim subgroup analysis from an ongoing prospective study evaluating hyperspectral imaging for MGMT promoter methylation in gliomas. J Neurooncol. 2025. PMID: 41247617. doi:10.1007/s11060-025-05340-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。